Robin Adelstein’s pragmatic approach to the practice of law is informed by her experience, having served as in-house counsel at Swiss healthcare company Novartis and UK alcohol beverage leader Diageo before becoming North American General Counsel of Sandoz, the generics and biosimilars division of Novartis. Whether involving pharmaceuticals, consumer products or other industries, Robin has advised her clients on a wide variety of antitrust issues and directed material litigation and government investigations to positive results. As a former General Counsel of a multibillion-dollar company, Robin knows first-hand the importance of providing prompt, accurate and practical advice on legal and compliance issues, particularly in the context of balancing complex business objectives. Robin also understands the challenges with managing outside counsel, having redesigned and run the Novartis Preferred Firm Program globally.
Working group to update pharmaceutical merger review in the US, Canada, UK and EuropeNorton Rose Fulbright, Robin Adelstein, Amanda Wait, Richard Wagner, Ian Giles, Jay Modrall and Marta Giner Asins, 31 March 2021